GlassScriptPhysician profile
Jinny E Chang
NPI 1336266857
$13,653.71
in general payments reported to CMS, 2019-2025
32 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,567 · 2020: $1,629 · 2021: $2,118 · 2022: $2,303 · 2023: $1,362 · 2024: $862 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525 · Consulting Fee: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.41 |
| Consulting Fee | $1,512.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,539.43 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Pharming Healthcare, INC. | $1,490.25 | 2019-2025 | Ruconest |
| Glaxosmithkline, LLC. | $1,488.31 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $816.71 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $806.86 | 2019-2025 | Hizentra, Haegarda |
| Regeneron Healthcare Solutions, INC. | $667.30 | 2019-2025 | Dupixent |
| Genzyme Corporation | $653.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $649.71 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $631.17 | 2019-2022 | |
| Pfizer INC. | $566.87 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $424.95 | 2019-2025 | |
| Shire North American Group INC | $372.04 | 2019 | |
| Alk-Abello, INC | $366.59 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Optinose US, INC. | $322.04 | 2019-2025 | |
| Incyte Corporation | $290.61 | 2021-2025 | Opzelura |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $250.27 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $211.78 | 2019-2023 | Xolair |
| Biocryst US Sales Co., LLC | $199.29 | 2022-2025 | Orladeyo |
| Octapharma USA, INC. | $127.14 | 2020-2025 | Cutaquig |
| Ionis Pharmaceuticals, INC. | $95.78 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $92.75 | 2019-2021 | |
| Bio Products Laboratory USA, INC. | $89.95 | 2019-2023 | Gammaplex, Coagadex |
| Greer Laboratories, INC. | $85.67 | 2024-2025 | Oralair, Palforzia |
| Covis Pharma Gmbh | $74.20 | 2022-2023 | |
| Kaleo, INC. | $70.20 | 2020-2023 | Auvi-Q |
| Hikma Pharmaceuticals USA | $68.65 | 2023-2025 | Ryaltris |
| Organon LLC | $53.45 | 2025 | Nexplanon |
| Ars Pharmaceuticals Operations, INC. | $40.65 | 2025 | Neffy |
| Horizon Therapeutics Plc | $39.87 | 2019-2020 | |
| Leo Pharma INC. | $27.36 | 2022 | |
| Aimmune Therapeutics, INC. | $20.51 | 2023 | |
| Merck Sharp & Dohme LLC | $19.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinny Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.